訓修實業(01962.HK)完成配售3318萬股籌資5049萬港元
格隆匯9月26日丨訓修實業(01962.HK)公佈,2019年9月20日,公司與賣方及配售代理訂立配售協議且與Evergreen Enterprise Holdings Limited(“賣方”)訂立認購協議,據此,賣方已同意委任配售代理且各配售代理已個別同意擔任代理,盡最大努力促使不少於六名承配人按每股配售股份的配售價購買最多合共4000萬股配售股份;及賣方已同意按每股認購股份的認購價認購最多4000萬股認購股份。
配售事項已於2019年9月26日完成,合共配售3318萬股。本公司已收到所得款項淨額總額約5049萬港元,並擬將所得款項淨額用於清償本集團未償還負債。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.